The Experts below are selected from a list of 58983 Experts worldwide ranked by ideXlab platform
Masoud Dara - One of the best experts on this subject based on the ideXlab platform.
-
reducing tuberculosis transmission a consensus document from the world health organization Regional Office for europe
European Respiratory Journal, 2019Co-Authors: Giovanni Battista Migliori, Edward A Nardell, Askar Yedilbayev, Lia Dambrosio, Rosella Centis, Marina Tadolini, Martin Van Den Boom, Soudeh Ehsani, Giovanni Sotgiu, Masoud DaraAbstract:Evidence-based guidance is needed on 1) how tuberculosis (TB) infectiousness evolves in response to effective treatment and 2) how the TB infection risk can be minimised to help countries to implement community-based, outpatient-based care. This document aims to 1) review the available evidence on how quickly TB infectiousness responds to effective treatment (and which factors can lower or boost infectiousness), 2) review policy options on the infectiousness of TB patients relevant to the World Health Organization European Region, 3) define limitations of the available evidence and 4) provide recommendations for further research. The consensus document aims to target all professionals dealing with TB (e.g. TB specialists, pulmonologists, infectious disease specialists, primary healthcare professionals, and other clinical and public health professionals), as well as health staff working in settings where TB infection is prevalent.
Lisa Jacquescarroll - One of the best experts on this subject based on the ideXlab platform.
-
building immunization decision making capacity within the world health organization european region
Vaccine, 2020Co-Authors: Liudmila Mosina, Siddhartha Sankar Datta, Abigail Shefer, Kathleen F Cavallaro, Louise Henaff, Christoph Steffen, Lisa JacquescarrollAbstract:A National Immunization Technical Advisory Group (NITAG) is a multi-disciplinary body of national experts that provides evidence-based recommendations to policy-makers, assisting them in making sound immunization policy and programme decisions. The World Health Organization (WHO) Regional Office for Europe is working to strengthen the capacity of newly-established NITAGs and has targeted efforts on low- and middle-income countries. The Regional Office, in collaboration with WHO Headquarters and USA Centers for Disease Control and Prevention (CDC), developed a new training strategy and held training workshops to improve NITAGs' functioning and ability to make evidence-based recommendations. Feedback from countries that participated in trainings indicated that the updated training materials and interactive approach with follow-up technical support enabled them to align their NITAG charters and processes with WHO recommendations. To ensure continued progress, global and Regional partners such as WHO and CDC should continue providing technical support to recently established NITAGs.
Giovanni Battista Migliori - One of the best experts on this subject based on the ideXlab platform.
-
reducing tuberculosis transmission a consensus document from the world health organization Regional Office for europe
European Respiratory Journal, 2019Co-Authors: Giovanni Battista Migliori, Edward A Nardell, Askar Yedilbayev, Lia Dambrosio, Rosella Centis, Marina Tadolini, Martin Van Den Boom, Soudeh Ehsani, Giovanni Sotgiu, Masoud DaraAbstract:Evidence-based guidance is needed on 1) how tuberculosis (TB) infectiousness evolves in response to effective treatment and 2) how the TB infection risk can be minimised to help countries to implement community-based, outpatient-based care. This document aims to 1) review the available evidence on how quickly TB infectiousness responds to effective treatment (and which factors can lower or boost infectiousness), 2) review policy options on the infectiousness of TB patients relevant to the World Health Organization European Region, 3) define limitations of the available evidence and 4) provide recommendations for further research. The consensus document aims to target all professionals dealing with TB (e.g. TB specialists, pulmonologists, infectious disease specialists, primary healthcare professionals, and other clinical and public health professionals), as well as health staff working in settings where TB infection is prevalent.
Seyed Moayed Alavian - One of the best experts on this subject based on the ideXlab platform.
-
prevalence of hepatitis c virus genotypes among patients in countries of the eastern mediterranean Regional Office of who emro a systematic review and meta analysis
Hepatitis Monthly, 2016Co-Authors: Farzin Sadeghi, Mostafa Salehivaziri, Amir Almasihashiani, Mohammad Gholamifesharaki, Reza Pakzad, Seyed Moayed AlavianAbstract:Context Hepatitis C virus (HCV) infection is a major global public health issue. The Eastern Mediterranean Regional Office (EMRO) of the world health organization (WHO) seems to have one of the highest prevalence rates worldwide, with at least 21.3 million HCV-infected patients. Objectives The aim of the present study was to review systematically all epidemiological data related to the prevalence of HCV genotypes in infected patients in EMRO countries. Data sources A systematic search was conducted of peer-reviewed journals indexed in electronic databases (PubMed, Scopus, ISI, PakMediNet, and IMEMR, and Persian-specific databases including SID, Iran Medex, and MagIran). Study selection A systematic search was performed with temporal limits (papers published between January 2000 up to June 2015), regarding the prevalence and distribution of HCV genotypes in EMRO countries. Data extraction The prevalence rates of HCV genotypes were pooled by metan command in Stata 14. Statistical heterogeneity was explored using the I-square at the 5% significance level. Publication bias was assessed, graphically and statistically, by funnel plot and Begg and Egger tests. Results A total of 563 records were identified through the electronic search. Of these records, 134 studies comprising 67681 HCV-infected individuals were included in the meta-analysis. In Iran, subtype 1a was the predominant subtype with a rate of 42% (95% CI, 39 - 46), followed by subtype 3a, 35% (95% CI, 31 - 38). In Pakistan, Subtype 3a was the most common subtype with a rate of 56% (95% CI, 49 - 62), followed by subtype 3b, 10% (95% CI, 7 - 12). In Saudi Arabia and Egypt, genotype 4 was the most prevalent genotype with a rate of 65% (95% CI, 59 - 72) and 69% (95% CI, 36 - 100) respectively. In Tunisia and Morocco, subtype 1b was the most common subtype with a rate of 69% (95% CI, 50 - 88) and 32% (95% CI, 7 - 56) respectively. Conclusions The genotype distribution of HCV takes diverse patterns in EMRO countries. Genotypes 1 and 3 were predominant in Iran and Pakistan, while genotype 4 and 1 were the most common genotypes in the Middle East Arab countries and North African Arab countries. Understanding the genotypes of HCV can help policy makers in designing good strategies for treatment.
Daniel E Sesse - One of the best experts on this subject based on the ideXlab platform.
-
the world health organization african region laboratory accreditation process improving the quality of laboratory systems in the african region
American Journal of Clinical Pathology, 2010Co-Authors: Guymichel Gershydamet, Philip Rotz, David Cross, El Hadj Belabbes, Fatim Cham, Jeanbosco Ndihokubwayo, Glen Fine, Patrick Njukeng, Souleymane Mboup, Daniel E SesseAbstract:Few developing countries have established laboratory quality standards that are affordable and easy to implement and monitor. To address this challenge, the World Health Organization Regional Office for Africa (WHO AFRO) established a stepwise approach, using a 0- to 5-star scale, to the recognition of evolving fulfillment of the ISO 15189 standard rather than pass-fail grading. Laboratories that fail to achieve an assessment score of at least 55% will not be awarded a star ranking. Laboratories that achieve 95% or more will receive a 5-star rating. This stepwise approach acknowledges to laboratories where they stand, supports them with a series of evaluations to use to demonstrate improvement, and recognizes and rewards their progress. WHO AFRO’s accreditation process is not intended to replace established ISO 15189 accreditation schemes, but rather to provide an interim pathway to the realization of international laboratory standards. Laboratories that demonstrate outstanding performance in the WHO-AFRO process will be strongly encouraged to enroll in an established ISO 15189 accreditation scheme. We believe that the WHO-AFRO approach for laboratory accreditation is affordable, sustainable, effective, and scalable.